John Robertson, MD

Dr. Robertson on Subgroup Analysis of the FALCON Trial for HR+ Breast Cancer

December 9th 2016

John Robertson, MD, professor of Surgery, University of Nottingham, Royal Derby Hospital Centre, United Kingdom, discusses a subgroup analysis of the FALCON trial, which compared treatment with fulvestrant (Faslodex) versus anastrozole (Arimidex) in patients with HR-positive advanced breast cancer.